Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ12170,50
KB-0,77
PKN86,7286,772,31
Msft503,46503,490,40
Nokia4,2524,3-2,25
IBM283,79283,89-1,25
Mercedes-Benz Group AG52,9552,970,00
PFE25,6825,69-0,37
11.07.2025 21:36:48
Indexy online
AD Index online
select
AD Index online
 

  • 30.06.2025 10:28:48
Kura Oncology (Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
5,00 3,06 0,16 250
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 11.07.2025
Popis společnosti
Obecné informace
Název společnostiKura Oncology Inc
TickerKURA
Kmenové akcie:Ordinary Shares
RICKURA.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.09.2024
Počet zaměstnanců k 31.12.2023 142
Akcie v oběhu k 04.11.2024 77 763 750
MěnaUSD
Kontaktní informace
Ulice12730 HIGH BLUFF DRIVE, SUITE 400
MěstoSAN DIEGO
PSČ92130
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 585 008 800
Fax13026555049

Business Summary: Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Kura Oncology Inc revenues was not reported. Net loss increased 41% to $154.8M. Higher net loss reflects Research and development - Balancing val increase of 61% to $73.9M (expense), General and administrative - Balancing increase of 57% to $39M (expense), Payroll related expenses increase of 19% to $32.6M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 11.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerTroy Wilson5521.08.2018
Chief Operating OfficerKathleen Ford7712.08.201912.08.2019
Chief Medical OfficerStephen Dale5224.08.202024.08.2020
Chief Commercial OfficerBrian Powl5014.08.202314.08.2023
Chief Legal Officer, SecretaryTeresa Bair5318.10.202118.10.2021